|
|
|
By Ed Miseta, chief editor, Clinical Leader
Research firm Industry Standard Research has released the latest edition of its Phase II/III Study Trends and Market Outlook (2022-2026) report. The goal of the report is to provide readers with a high-level view of the Phase 2/3 clinical development space to illustrate current market dynamics and inform strategic planning.
|
|
|
Article
|
By Malcolm Horsley,
MRN - Medical Research Network
Years of experience, bolstered by continuous improvement efforts, have positioned MRN at the forefront of decentralized clinical trial execution, from in-home care to the MRN eClinical suite of technology.
|
|
White Paper
|
IQVIA Research & Development Solutions
The development of new treatments has been slow, with only two approved disease-modifying drugs that offer limited benefit. But significant advances in immuno-neurology have set the stage for promising novel treatments that could offer hope to these families and change the course of this disease.
|
|
White Paper
|
By Yves Massicotte,
Ropack Pharma Solutions
Learn why the trends in the packaging of prescription and over-the-counter drugs indicate continued growth in the blister packaging market.
|
|
Webinar
|
Thermo Fisher Scientific
Combining drugs that may have been shelved due to a variety of reasons with established, safe, and approved drugs has the potential to bring safer, effective therapies to patients.
|
|
White Paper
|
Premier Research
Given the right expertise, Rx-to-OTC conversions are easier to achieve with less time and expense than one might expect for a regulatory exercise.
|
|
|
|
|
By Kimberly Cash and Kyle Felmet, Two Labs
Medical communications help crystalize the nuances of cell and gene therapies for patients and healthcare providers. For a successful cell or gene therapy launch, you'll need to draw attention to stakeholders early in clinical trials to effectively inform them of the value of the therapy in development. This article shares key tips for an effective strategy.
|
|
|
Article
|
By Susan Jalbert,
Oracle Health Sciences
The outsourcing trend is being driven in response to the ever-increasing size, complexity, duration, and cost of clinical trials. Sponsors primarily outsource to CROs to control operational and infrastructure costs, allowing them to concentrate on what they do best — drug development. However, with outsourcing, processes and systems are often duplicated or disparate. You need a unified eClinical ecosystem for “trusted collaboration.”
|
|
Article
|
Informa Pharma Intelligence
From decentralized trials to real-world data, take a look at top trends, their impact on patient enrollment and more, as well as ways to stay ahead of the curve.
|
|
Article
|
By Amy Ripston,
4G Clinical
Managing protocol versions at the site level and the broader protocol amendment at the sponsor level go hand in hand. Learn why neither is simple, but both sides of the equation must be taken into consideration when designing a study.
|
|
White Paper
|
Slope
Discover how an eClinical supply chain management (eCSCM) platform is crucial in order to replace manual processes and have capabilities that streamline the coordination of collaborators and the communication between them.
|
|
Webinar
|
Greenphire
In this webinar, learn what sites, CROs, and patient advocacy groups are doing to make clinical trials accessible to more patients.
|
|
|
Article
|
By Eyal Wultz and Bremer Louw,
Bioforum the Data Masters Inc.
How can sponsors ensure SDTM compliance while still maintaining the efficiency and speed necessary to meet their trial timelines and milestones?
|
|
Infographic
|
ISR Reports
In Q1 and Q2 of 2022 ISR surveyed 132 sponsors worldwide who outsource Phase 2/3 studies and asked them to identify attributes that are important to them when selecting an outsourcing partner. The research revealed that respondents valued Operational excellence and Therapeutic expertise highly when choosing a provider for their Phase 2/3 studies. To learn more about outsourcers’ Phase 2/3 study needs, market dynamics, and their use of different service providers.
|
|
Podcast
|
Parexel International
Chris Learn, head of cell and gene COE at Parexel, discusses his participation at the recent Clinical Research Virtual Summit hosted by the Society for Immunotherapy of Cancer, and the implications for clinical research.
|
|
White Paper
|
Novotech
Delve into how China is now more aligned with international standards, especially the U.S. FDA, enabling biotech firms to streamline processes and timelines, which has significantly recharged biotech innovation.
|
|
Webinar
|
TransPerfect
In this webinar, review some key changes to the European Union regulatory framework, in particular the EU Clinical Trial Regulation (EUCTR) that came live earlier this year, and how this affects study start-up.
|
|
Article
|
By Liisa A. Palmer, Ph.D.,
Merative
Explore how real-world data, and administrative claims data specifically, is being evaluated to support activities in the clinical development space.
|
|
|
|
|
|
|
|
|
PerkinElmer Informatics, Inc
|
|
|
|
|
|
Have you heard of Life Science Leader?
Check it out today for access to candid interviews with top-tier executives on how they do business.
|
|
|
Connect With Clinical Leader:
|
|
|
|
|
|
|
|